Highlights

• SER150 clinical study in Australia is still delayed after Covid19 lockdowns
• Serodus received Australian governmental refund (RDTI) for the SER150 Cl-009 study activities.
• The Group qualified for and received a “Patent Voucher” from the Ministry of Commerce in Denmark supporting the patent strategy of the subsidiary Phlogo ApS.

Go to the report: Serodus ASA QR 2022 – Q1